incomplete Freund's adjuvant
Phase 2Biologic
Incomplete Freund's adjuvant is used in research settings to boost the immune system's response to vaccines and experimental treatments, helping scientists test how well new medicines work.[1] incomplete Freund's adjuvant is currently being investigated across 2 indications[3], with its most advanced program in Phase 2.[1]
incomplete Freund's adjuvant is one of 45 biologic programs targeting Digestive System Neuroendocrine Neoplasm. It is currently in Phase 2.
2
Indications
53
Total Trials
2
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
258 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Empliciti
Bristol-Myers SquibbPhase 3
Fludara
SanofiPhase 3
TALVEY
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Elranatamab
PfizerPhase 3
Cytosar
TevaPhase 3
Sylvant
RRECORDATI GROUP
Phase 3
Linvoseltamab
RegeneronPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Melanoma20 trials
Show 17 more trials
Metastatic Melanoma16 trials
Show 13 more trials
Non-Small Cell Lung Cancer2 trials
Breast Cancer2 trials
11 more indications
Primary Peritoneal Cancer1 trial
Adjuvant1 trial
Multiple Myeloma1 trial
Myelodysplastic Syndrome1 trial
Gastrointestinal1 trial
Renal Cell Carcinoma1 trial
Fallopian Tube Cancer1 trial
Metastatic Neuroendocrine Tumor1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details